Preventive and Therapeutic Euphol Treatment Attenuates Experimental Colitis in Mice
Figure 3
Preventive treatment with euphol changes colonic protein levels and mRNA expression of inflammatory mediators.
At the end of 7 days, colon tissue was collected and processed for cytokine levels and mRNA expression. (A–D) Enzyme-linked immunosorbent assay. Preventive treatment with euphol (30 mg/kg, p.o.) reduced colonic levels of interleukin-1β (IL-1β) (A), keratinocyte-derived chemokine (CXCL1/KC) (B), macrophage inflammatory protein-2 (MIP-2) (C) and monocyte chemoattractant protein-1 (MCP-1) (D). (E–H) Real-time PCR. The same scheme of treatment with euphol also impaired the increase colonic mRNA expression of IL-1β (E), CXCL1/KC (F), tumor necrosis factor-α (TNF-α) (G) and interleukin-6 (IL-6) (H). The real-time PCR assay was performed in duplicate and GAPDH mRNA was used to normalize the relative amount of mRNA. Data are reported as means ± S.E.M. of 8 to 10 mice per group and is representative of three independent experiments. #P<0.05 vs. control healthy group (non colitic); *P<0.05 vs. DSS-treated group.